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Abstract 
In this paper the authors perform the analysis of molecular and morphological factors 
influencing the survival of patients with gastric cancer (n = 221). They analyzed the survival 
rate in this group of patients based on the analysis of molecular markers VEGFR, p53, Her2, 
Ki-67. Measured role in the survival such factors as the degree of differentiation of primary 
gastric tumors, the presence of microscopic tumor involvement of perineural and perivascular 
spaces, the degree of invasion to gastric wall by T1 = 1 and to T4a = 4, T4b = 5, number of 
regional lymph nodes affected by metastasis, and other factors. As an arbitrator used survival 
curves calculated by the method of R. J. Cox, time of lifespan, measured in months, as well as 
a comparison of the areas under the curves of survival. 
Keywords: gastric cancer (GC), lymph node dissection, multiorgan resection, 
immunohistochemistry, genetic classification. 
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Introduction 
The study of survival of cancer patients is in the focus of our diligent attention in the 
clinical and experimental oncology. Many factors affect the quantitative and qualitative 
analysis of lifespan of treated patients. At the moment not aware of any tool or instrument that 
could measure the anticipating duration of the life expectancy of the treated individual. 
However, based on the mathematical analysis of many factors at once, it is possible to predict 
the life expectancy of patients with gastric cancer. It depends on many factors, which are 
variable, ie, they may vary by the influence of many factors. Our task is to follow up such 
trends, when knowing the patient's age, stage of disease, the exponents of aggressiveness of 
the tumor biology, you can make a tentative forecast duration of the forthcoming life after 
surgery. It does not consider the possibility of other causes of death of the patient, non-
oncological disease (heart attacks, strokes, other reasons). One of the most frequently asked 
question is "how long lifespan you, as a doctor, can give?" The doctor did not provide the 
man's life, it is not in his power; but given the significant clinical experience, mathematical 
tools available to us today, it would be a misunderstanding at least do not try to do it. Only on 
the very surface are seen such factors as: 
1. Cancer in younger people proceeds more aggressively, and its biology and the rate 
of metabolic processes, the cell cycle velocity is different from the torpid, sometimes lasting 
for decades cancer in the elderly 
2. The stage of the tumor process is constantly changing depending on the revision of 
TNM classification. For instance, once it meant N1 (which is logical) affected lymph node 
metastases paragastrical lymph nodes; then N1 stage means the involvment from 1 to 6 
regional lymph nodes by metastases, and now N1 stage naturally means only 1 or 2 lymph 
nodes involvment. Describing this fact in terms of figures, we can say that N1 ≠ N1 ≠ N1. A 
survival statistics depending on the stage tends to be unchanged, as data changes in GC TNM 
classification [9, 10, 21] occurred during last 10 years. 
3. The degree of differentiation, G, and the number of mitosis (proliferation index Ki-
67) are factors in determining the aggressiveness of tumor growth, but nowhere in the 
literature you will not find such a forecast. We have not seen any literature source, wherein a 
specific percent survival would indicate that the survival T3N1MoG1 have 40% and 30% 
T3N1MoG4, for example. In this age of high technology and the abundance of information on 
various topics in various human activity fields have not demonstrated similar statistics. In the 
best case, you will find some data that survival in stage I GC within 5 years tends to be 80-
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90%, II stage 60-70%, III 30-40% or less, and patients in stage IV, even operated radically, 
cross infrequently threshold of 20% survival. 
 
Materials and methods 
Presented study was performed in the abdominal surgical department of Odessa 
Regional Oncology Center, included 221 patients undergoing surgery for gastric cancer in the 
period 2007-2013. The study was retrospective, single-center, non-randomized. The average 
age of 60,88 ± 10,5 years, men - 180, women - 41. In total in 143 pts performed gastrectomies 
and in 78 – distal subtotal resection. Gastrectomy procedure performed by Bondar method to 
form a loop-like anastomosis. Subtotal resection of the distal part with the formation in most 
cases retrocolic gastroenteroanastomosis by Billroth-2, Finsterer-Hofmeister modification.The 
mortality rate was 1.2%, 84% operability. It takes into account the survival of this group of 
patients by stages and by type of operation. Survival Analysis is shown in Table 1. 
 
Table 1. Effect of lymphadenectomy volume on life expectancy based on the stage. 
*Note: D2 +, according to modern Japanese literature on the subject indicates 
execution D2 dissection with simultaneous para-aortic lymphadenectomy. 
Stage of the disease Type of 
lymph 
nodes 
dissection 
Life expectancy months. 
1B * D2 + 20.5 ± 8.4 p = 0.25 
 D2 19.6 ± 7.5 
D1 13.3 ± 10.64 
2 D2 + 48.0 ± 7.5 p = 0.00003 
 
 
D2 20.5 ± 12.6 
D1 25.7 ± 12.6 
3A D2 + 28.5 ± 5.9 p = 0.01 
 
 
D2 23.6 ± 5.9 
D1 15.3 ± 5.9 
3B D2 + - p = 0.21 
 
 
D2 13.0 ± 11.1 
D1 22.7 ± 11.1 
4 D2 + 21.4 ± 6.0 p = 0.59 
 
 
D2 17.3 ± 6.0 
D1 18.3 ± 6.0 
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Photo 1. Intraoperative photo made para-aortic lymphadenectomy and retroperitoneal 
peritonectomy. 
 
Table 2. Life expectancy measured in months, depending on the stage and type of 
surgery (7th revision of TNM classification). 
Stage of the 
disease 
Type of operation Average life 
expectancy in the 
group, months. 
The duration of life, 
depending on the type of 
treatment, months. 
IA Advanced \ MVR * 48 No data 
D2 lymph node dissection 48 
standard No data 
IB Advanced \ MVR 23.5 24.7 
D2 lymph node dissection 21.8 
standard 24 
II Advanced \ MVR 34.1 48 
D2 lymph node dissection 20.3 
standard 34 
IIIA Advanced \ MVR 26.2 34.5 
D2 lymph node dissection 28.5 
standard 15.6 
IIIB Advanced \ MVR 27.5 No data 
D2 lymph node dissection 15 
standard 40 
IV Advanced \ MBVR 20.75 22.3 
D2 lymph node dissection 20.4 
standard 21.1 
*MVR - multiorgan (multivisceral) resection \ gastrectomy means that resected \ 
removed 3 or more adjacent organs. 
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Photo 2. Component of multiorgan resection – a general view of resected liver right 
lobe. Resection performed using RITA technology using a specific electrode for resection of 
the liver, of Dr. Nagi Habib from London Hammersmith Center. 
 
General characteristics of patients with multiorgan interventions performed is shown 
below. Intramural spread into esophagus registered in 31 (14.03%) patients that required 
resection subphrenic and, in some cases, intradiaphragmal esophageal segments. In 3 cases 
performed operation according to Osawa-Garlock with resection of intratoracal esophageal 
segment (13,58%). In 8 cases - resection of subdiaphragmatic segment by Savinyh (3.62%). 
Duodenum involvment - in 2 (0.91%) patients were classified morphology be the greatest 
depth of invasion. Pancreatic resections were performed in 44 patients (19.91%), of which the 
true histologicaly proofed involvement of pancreas found in 5 patients (2.26%), atypical liver 
resection – in 9 patients (4.07%), anatomical resection – in 3 patients (1.36%). Splenectomy 
performed in 153 cases (69.23%), most frequently - as component of LND + D1 and higher. 
In 5 cases there was detected splenic capsula metastases (2.26%). In 2 cases, the splenic gate 
dissection was performed as a component of splen-sparing operations (0.91%). 
The life of a particular cancer patient - this is not only Story about the stage, type and 
extention on an adjacent structures. In the next group of prognostic determinants should be 
necessarily included the age of patient, tumor volume (ie number of cell colonies which do 
not take into account in the TNM), the degree of genetic "controllability" of the cell cycle (the 
severity of the expression of TP53 oncoprotein by immunohistochemical analisis - IHC) 
expression of neoangiogenesis VEGFR markers [11, 12, 13, 14, 15]. 
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Table 3. The differences between expressing oncoproteins established by the authors 
in sole order to form the equivalent groups of patients. 
 TP53 VEGFR-C Ki-67 Her2 \ new 
"Positive" reading 
marker 
11-100% "++" 
"+" 
0-20% "+" 
"++" 
"+++" 
"Negative" reading 
marker 
0-10% «±» 
"-" 
21-100% "-" 
 
Her2 \ new marker for gastric cancer is to define as a "positive" even in the case of 
expression "+" corresponding oncoprotein - Sheffield Brandon [26].  
 
Table 4. Dependence of pts longevity (months) accordint to the stage, and histological 
type respectively. 
 
Terashima et al. [24] found that her2-positive gastric cancer has the best indicators of 
disease-free and overall survival compared with her2-negative.Kim et al. [25] The study by 
Cox survival at different markers expression (EGFR, VEGF, VEGF-D, VEGFR-2, VEGFR-3, 
TGF-α, TGF-β1 and TGF-β RII) Found that VEGF-D can be used as a prognostic factor and 
its high expression is associated with worse overall survival of patients. Thus, along with the 
third immunohistochemical marker p53 (about him, or rather its protein TP53, has described 
above), all of them can be used as factors of prognosis, and individualization of therapy. The 
Stage of 
the 
disease 
View 
dissect
ion 
Differential-
ings 
The presence of 
tumor emboli 
The presence of 
residual tumor 
tissue 
The presence of 
perineural 
invasion 
G1/G2 G3/G4 Vo V1 Ro R1 Nev/0 Nev/1 
IA D2 + - - - - - - - - 
D2 48 - 48 - 48 - 48 - 
D1 - - - - - - - - 
IB D2 + 26.5 21 26 18 24.7 - 26 18 
D2 21 24 21 24 22.8 - 21 21 
D1 24 - 24 - 24 - 24 - 
II D2 + - 48 - 48 48 - - 48 
D2 27 13 24 18.5 20.3 - 37.3 24 
D1 34 - 32 24 29.3 48 29.6 - 
IIIA D2 + 24 33.8 21 36 29.6 - 48 29.6 
D2 27.3 22.1 20.8 27 25.4 13 24.5 24 
D1 13.3 17 19.6 20 17.4 3 15.6 16 
IIIB D2 + - - - - - - - - 
D2 11.3 - 11.3 24 16.3 4 11.25 24 
D1 - 40 40 - 40 4 40 - 
IV D2 + 11.8 thirty 17.7 28.3 23 34 18.6 28.9 
D2 20.9 20.2 22.4 9 19.9 22.4 20.9 - 
D1 24 25.2 19.4 20.5 21 13.5 19.6 - 
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combination of these types of markers have the potential of molecular typing (epigenetic) 
forms of stomach cancer, just as immunohistochemical markers of breast cancer help 
epigenetically typed breast cancer.  
Results 
Intriguing results on a sample of 221 patient study showed a combination of 2 or more 
immunohistochemical markers. Because the ultimate goal was to form a group with 
independent survival. This was the first step towards drawing up mosaics of genetic types of 
GC. Genetic types of GC have the highest potential to create groups of patients with different 
survival, i.e. statistically independent objects. 
 
Table 5. The corresponding graphs given in the diagram, the percentage survival. The 
area under the curve represents the product of years of survival \ patients (month x number of 
patients) and is a more meaningful indicator than a long duration of life. Yellow color 
indicates the results that are indicative of further research in this area. 
Duration life 
months. 
MVR + D2 
lymph node 
dissection,% 
MVR% D2 lymph node 
dissection,% 
3 96.97 95.24 97.3 
6 90.91 90.48 94.52 
9 84.85 85.72 91.65 
12 81.71 80.96 88.7 
15 75.43 76.2 85,64 
18 72.15 71.44 82.47 
21 68.71 68.97 79.17 
24 65.1 66.42 72.57 
27 61.27 61.31 69.12 
thirty 57.18 58.65 65.48 
33 52.78 53.32 61.63 
36 47,99 50,51 57.52 
39 42.65 47,54 53.1 
42 36.56 41,61 44.27 
45 24,51 35.67 35.45 
48 12.58 32.43 28.36 
60 0 25.97 18.91 
72  19.51 0 
84  13.08  
96  6.72  
108  0  
The area under the 
curve of survival, S. 
19760 73 26505.99 24878.1 
Number of patients 8 35 5 
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An interesting idea was used to determine significant differences between survival 
curves not only purely numerical (p criterion, odds ratio – OR), but also visually-numeric 
criteria. An example of this approach is to measure the area under the curves of survival 
differences. The table above shows some average duration of life of patients group without 
regard to its population. The area under the curve is the product of life expectancy of patients 
on their numbers, which in our opinion are more fully reflects the degree of influence on the 
treatment group. 
Below the graphs shows differences in survival depending on the GC varying severity 
immunomorphological tumor characteristics. 
 
Figure 1. Survival of patients with gastric cancer with vegfr-p53-her2+ki67-set and 
vegfr-p53+her2+Ki67+set. P = 0.017195.Calculations were made with the help of 
mathematical capacity of calculators available online http://statpages.info/. 
 
Worst prognosis of survival, focusing on a group of patients who had made up the so-
called "Triple-negative" GC, in analogy to a similar form of breast cancer. It is characterized 
by the absence of neoangiogenesis manifestations, TP53 protein expression and lack of 
response to the analyzed slides immunohistochemical dyes protein c-erbB2 [3, 5, 16, 17, 18, 
19, 20]. 
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Figure 2. Graph of survival so-called "Triple negative GC" VEGFR-p53-Her2-. 
 
An interesting feature identified during the analysis of marker combinations, VEGFR-
p53-Her2+Ki-67-set were highlighted highly differentiated forms without growth into 
adjacent structures, exophytic growth pattern, with no signs of aggressive growth. Those what 
are commonly referred to as local forms, promising in terms of long-term survival even in 
loco-regional stage. But overall survival in this group, as shown in Fig. 4 will be 
comparatively low. They are is histologically "good" cancers with a "bad" IHC and thus 
pretty well prognosis. 
 
Table 6 Cumulative impact on survival criteria G, V, R, Nev patients, regardless of the 
stage and method of dissection, months. 
 G V R Nev 
G1 \ 
G2 
G3 \ 
G4 
Vo V1 Ro R1 Nev \ 0 Nev \ 1 
The average 
duration of 
observation, 
months 
23.8 ± 
6.3 
15.9 ± 
6.3 
23.6 ± 
5.6 
19.2 ± 
5.6 
24.7 ± 
7.1 
10.6 ± 
7.1 
24.6 ± 
6.0 
12.9 ± 
6.0 
reliability 
differences 
p = 0.079 
 
p = 0.25 
 
p = 0.0075 
 
p = 0.0092 
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Figure 3. Visualisation of effect of multiorganic resection (MOR, MVR) on survival of 
patients with VEGFR-p53+Her2-Ki-67+set of markers. The group called "group of the 100th 
month." 
 
Found a group where the implementation of multiorgan resections impact on survival 
of patients with gastric cancer in the later stages of observation - after 100 months. The main, 
the critical feature group VEGFR-p53+Her2-Ki-67+ was the absence of metastasis to regional 
lymph nodes even in the presence of T4 tumors. Why in this group were more effective MVR, 
and not D2 LND remains a puzzle to us. 
We have recently made the conclusion: significant efficiency performance multiorgan 
resections in microsatellite-unstable GC [4, 6, 7, 8, 22]; mainly the absence of metastases in 
regional lymph nodes, as well as lack of capacity "occult" generalization, such as perineural 
growth. 
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Micrograph 1. Micrograph tumor "prominence" in the lumen of perineural stroke in 
the upper middle part of the microscopic picture. 
 
The survival rate of patients with gastric cancer is the criterion that allows you to 
properly assess the effectiveness of any therapeutic effects, diagnostic criteria and compare 
the methods of diagnosis and treatment of each other. Survival is an integrative index 
summing the duration of life of patients in the group for the purpose of calculating the 
average value. The peculiarity of mathematical methods of studying the survival mechanisms 
is to use probability theory to predict the 5-year survival rate. Even in the early stages of the 
application of these techniques in medical computing - and it was the so-called survival of the 
table - it was possible to calculate the 5-year survival rate in a sample of patients, some of 
whom were treated with at least 5 years ago. Thus, the time elapsed from the time difference 
between the treatment and control start and end points of therapy in all treated could be 
different. In practice, this results in the possibility of mathematical precision greater than 95% 
(which is enough for biomedical observations) calculate the group overall survival of patients 
exposed to a particular treatment. And then compare the resulting effects (survival change) by 
comparing survival curves. In the event that the difference between survival curves is 
statistically significantly different (or r˂0,05 OR≥1), the effect of the method is recognized 
clinically \ diagnostically valuable. Some researchers, thus, give more importance to visually 
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distinguish between two curves (the so-called estimate of the area size between the curves) as 
a marker of the presence and authenticity of differences. There are techniques, assessing p 
between certain points of the two curves in their places of maximum divergence (or, another 
embodiment in median time points, where the number of groups is halved); others allow to 
calculate the significance of differences between the curves p as two mathematical sets. There 
is a fairly large number of methods to calculate the significance of differences p: Student's, 
Pearson, Mann-Whitney-Wilcoxon. As calculation techniques and imaging survival rates: 
Kaplan-Mayer, Cox and others. 
In this sense, for example, the ability of any classification to form groups with 
significantly different survival rates of patients with evidence of the correctness of generated 
staging system. Because modern mathematical model of survival is objective, and the most 
perfect staging system was invented, is subjective and introduced artificially. Thus, the 
reliability calculation survival differences can evaluate not only the effectiveness of the 
treatment, but also the power of the diagnostic method. The term "group of independent 
survival" can be used to describe a set of survival rates of groups of patients with varying, 
e.g., the degree of differentiation of the primary tumor (G1-G2-G3-G4); with various primary 
objective tumor size (cm2); presence-absence perineural-perivascular infiltration. Finally, the 
most classical academic sources of differences - different localization of the tumor in the 
stomach. 
An interesting observation is conducted by the workpiece varying the concept of "the 
degree of malignancy" or "degree of biological aggressiveness" depending on the 
combination of IHC markers. This can hardly be called staging, because due to the small size 
of the group we could not identify 3-4 groups in each of the VEGFR, p53, Her2, Ki-67 
species. Therefore, the survival of a group seen as the Chief Arbiter of the aggressiveness of 
the cancer, making it a more "malignant" or, on the contrary more torpid and "benign". 
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Figure 4: Graph that shows the possibility of protein markers to create groups with 
different survival. 
Group 100 of month (blue arm) VEGFR-p53+Her2-Ki-67+ can be named group of 
"poor IHC set" because of the high proliferative potential Ki-67 [2], but relatively favorable 
prognosis. 
 
 
Figure 5. Charts visualising influence of D2 lymph node dissections (LND) and 
multiorgan resection on survival of patients with  combination VEGFR-p53+Her2-Ki-67+ 
markers. The group called "group of the 100th month" (overall survival of the group - a green 
dotted line). 
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When we analyzed the whole group of patients with gastric cancer (n = 221), charts 
the survival of patients with tumors of the gastric antrum, body and cardia parts. Encouraging 
was to see that there exists a system of coordinates (VEGFR-p53+Her2-Ki-67+), where 
"antral stomachs" live longer than traditionally "bad" in terms of long-term survival of 
patients operated for epithelial malignancies of body tumors and cardia-located lesions. 
 
Figure 6. Influencies of localization tumor in the stomach onto survival, patients with 
VEGFR-p53+Her2-Ki-67+set. 
 
Given data, the presence of the appropriate mathematical tools our capability to 
predict the life expectancy is acknowledged relatively high.  
The meaning of the invention is to find specific digital multipliers and mathematical 
formulas for the prediction of the estimated life expectancy of patients with GC and, 
respectively, some extra insight on personalization / individualization of complex treatment 
options subject. 
The method and formula may be used by surgeons and to personalize 
chemotherapeutical (her2 \ new, VEGFR) and surgical methods of individualizing treatment: 
depending on the invasion of the wall, the patient's age, affected lymph nodes, tumor size, 
tumor grade G and bioharassment p53 [1.23] . 
Figure 6, which demonstrated TP53 oncoprotein expression effect on survival. The 
green and blue curves represent the best survival situation. 
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Effect of high Ki-67 proliferative index in these groups of patients (green and blue 
survival curves) offset the influence of p53 expression. 
Detected digital values factors relevant variables and their relationships in the formula 
(e.g. x6 - "floating" variable, which characterizes the value concentration oncoprotein 
VEGFR) are the essence of the invention. 
Modifier degree of differentiation = 38.57020554889854 
Modifier p53 expression marker = 14.79373951516277 + x6 
Modifier variable degree of wall invasion = 10.631088579592571 
Modifier variable number of affected lymph nodes = -14.096156327772121 
Tumor size, measured by CT = -0.37371001935662385 
Variable characterizing the protein concentration her2 \ new = 2.2679620241496714 
Modifier variable characterizing the estimated time of life = -1.1666992349525311 
Modifier variable characterizing the protein concentration VEGFR- free variable (can 
be any). 
Figure 7. The combination of the presence of oncoproteinVEGFR with the presence of 
tumor emboli in a lumen of microscopic lymph vessels (histologically look like a slit), blood 
(component have smooth muscle in the wall) and venous-type worsen survival. 
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It is difficult to say why during neoangiogenesis protein present in the tumor itself is 
not always GC showed tropism for microscopic spreading (not always even in the step T4, 
which here n = 5). Apparently, in this case, the value had high proliferative index, low indices 
of p53 and CD 340. 
The degree of vascular (v, venous and ly, lymphatic) classified by engagement JRSGC 
[21]: 
v0, ly0 - no vascular invasion; 
v1, ly1 - minimum vascular invasion; 
v2, ly2 - mild vascular invasion; 
v3, ly3 - severe vascular invasion. 
 
 
Micrograph 2. Tumor extravasates in the lumen of the vessel muscle-type (visible 
smooth muscle) in the left middle portion of the microscopic pattern. 
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Thus possible to track the effect of various oncoproteins biological propensity of 
tumor involved in microvascular own environment, create new vessels to penetrate into them 
and create tumor emboli circulating tumor complexes. In fact, in Mikrofot. 2 illustrates one of 
such migrating complexes, ready to "sail". 
  
Table 7. Correlation between histological and immunohistochemical prediction 
markers in GC: tumor emboli and invasion into blood microvessels. The table shows 
correlations between various degrees of severity tumor vascular involvement and 
immunohistochemical expression of various markers. 
 p53 VEGFR-3 Ki67 Her2 \ new 
+ - + - + - + - 
 Vo 52 9 67 0 88 0 13 57 
V1 9 8 0 27 0 13 0 24 
V2 20 41 14 26 50 12 12 46 
 V3   31 18 0 54 12 13 13 23 
Σ 112 76 81 107 150 38 38 150 
R r˂0,0001 r˂0,0001 r˂0,0001 p = 0.711 
 n 95% CI n 95% CI n 95% CI n 95% CI 
OR 6,452 2,776 15.411 512.071 66.910 10719, 
582 
53.935 7.619 1084.5
91 
0.848 0,376 1,899 
Sensitivity
. 
0.464 0.409 0.503 0.827 0,774 0.839 0.587 0,560 0.587 0.342 0.209 0,496 
Spec. 0.882 0,800 0.938 0.991 0.951 1,000 1,000 0.893 1,000 0,620 0.586 0.659 
PPV 0.852 0,751 0.923 0,985 0.922 0,999 1,000 0.954 1,000 0,186 0,114 0.269 
NPV 0.528 0,479 0.562 0.884 0.849 0.892 0,380 0,339 0,380 0.788 0.745 0.838 
PLR 3,921 2,049 8.164 89.333 15.867 1728.20
3 
22.88 3,935 442.03
8 
0,900 0.506 1,453 
NLR 0,608 0,530 0.738 0.174 0.161 0,237 0,424 0.408 0.516 1,061 0.765 1,348 
OR - odds ratio, PPV - positive predictive value. NPV - negative predictive value. 
PLR - positive likelihood ratio. NLR - negative likelihood ratio. 
 
Table 8. Evaluation of correlation depending lifespan of histological factors prognosis 
in gastric cancer. 
The degree of 
correlation 
numerical range 
Pearson coefficient 
values 
The combination of prognostic factors 
Very weak correlation 0-0.2 Stage \ perineural growth stage \ grade, 
stage \ absence of perivasal invasion 
weak correlation 0,21-0,5 perivasal invasion \ grade, perivasal 
invasion \ perineural growth 
The average correlation 0,51-0,7 no 
high correlation 0,71-0,9 Residual disease \ perivasal invasion 
residual disease \ G 
Very high correlation 0,91-1 Perineurium. growth \ G differentiation 
Perineurium. growth \ The residual 
microscopyical disease 
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The claims COUNTING projected SURVIVAL: 
 
 
 
Where: G-degree of differentiation of gastric tumor. p53-positive or negative 
expression of TP53 oncoprotein. T-degree stomach wall involvment T1 = 1 and = 4 to T4a, 
T4b = 5. N-number of regional lymph nodes in which metastasis found. S-tumor area 
measured by CT or before surgery, or after removal of the drug pathologist. X-«floating 
variable». Her2-positive or negative expression of the corresponding oncoprotein. Month-
approximate (estimated) life expectancy, measured in months. 
 
Example: 
[38.6 * 2 + (14.8 + 1) + 10.6 * 4-14.1 * 5-0.37 * 20-2.27] /1.17=46,35 months. 
Gauss' method was used to solve the system of linear equations, variables and factors 
which make up the primary material studied in author`s thesis. 
(Details - http://mashukov2017.livejournal.com/763.html) 
 
Skipping more than 20 counting the steps, in order not to load readers' attention to the 
amount of calculations, we obtain the final step and the resulting variable factors G, x, p53, T, 
N, S, VEGFR, her2, month. 
 
Subtract the seventh row of the 6th row and restored its 
number X1 X2 X3 X4 X5 X6 X7 X8 b 
1 1 0 0 0 0 0 0 0 38.57020554889854 
2 0 1 0 0 0 -1 0 0 14.79373951516277 
3 0 0 1 0 0 0 0 0 10.631088579592571 
4 0 0 0 1 0 0 0 0 -14.096156327772121 
5 0 0 0 0 1 0 0 0 -0.37371001935662385 
6 0 0 0 0 0 0 1 0 2.2679620241496714 
7 0 0 0 0 0 0 0 1 -1.1666992349525311 
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Answer: 
x1 = 38.57020554889854 
x2 = 14.79373951516277 + x6 
x3 = 10.631088579592571 
x4 = -14.096156327772121 
x5 = -0.37371001935662385 
x7 = 2.2679620241496714 
x8 = -1.1666992349525311 
x6- free 
 
Discussion 
 
Of considerable interest is the relationship between encountered two key factors 
immunohistochemical factors TP53 and VEGFR: x2 = 14.79373951516277 + x6. 
Thus, the obtained factors that need to multiply the variables already known for 
survival values obtained in the routine practice of the abdominal oncosurgical department of 
Odessa Regional Oncological Center. The results obtained by experimentation using an 
existing mathematical tools available online. 
For example, https://www.symbolab.com/solver/system-of-equations-calculator. 
For a more compact form, available numeric values to 17 characters after the decimal 
point have been rounded up to 2-3 decimal places, which is sufficient for biomedical research. 
Research and the very essence of his decision has nothing to do with an attempt to accurately 
forecast the fate of cancer patients. There is no way to know the number of days, minutes and 
seconds of human life God provided. For different cancer sites there is a very specific 
information on the survival of patients in stages of the disease. There is now a substantial 
need for the possession of such background information for more specific clinical situations 
(the number of lymph nodes get involved, tumor volume, etc.). There must be solutions that 
can then be used as a consultative reference information for the patient, his family, planning 
the number of cycles of chemotherapy, the degree of aggressiveness of complex treatment, 
given the expencive  chemo medication, etc. Such motivation can play a role in the 
personalization\ individualization of therapeutic approaches. 
Survival, as has been repeatedly emphasized, is ts "Arbiter", proving the bright light 
on the effectiveness of the treatment modality or particular diagnostic test. Quality of life, no 
matter how beautiful it may be, never outweighs the importance of longevity. And no matter 
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how perfect the questionnaire, His Majesty the Time measured in seconds, minutes, hours, 
days, weeks, months, years of life will always be more objective criterion. As the most 
credible witness to the effectiveness of therapy. 
Conclusions 
1. Given the high awareness of patients and their relatives, and the growing 
dependence of the medical community of the total availability of medical information on 
various topics, there is an ongoing need for a more precise gradation dependency of survival 
of cancer patients from different clinical and morphological situations. 
2. Available mathematical, computer hardware and software tools becoming 
increasingly available to the practitioner who does not have special mathematical education. 
3. The results will always be purely advisory, reference, recommendation, as human 
life can not be measured using the most sophisticated mathematics and lies outside the limits 
of natural computing. 
4. Personification \ individualization of treatment regimens must contain some 
mathematical algorithms with many variables in order to provide affordable health care 
prognosis for the public community.    
5. This paper is an attempt to provide fairly detailed report to the main questions asked 
by patients and their relatives; and sheds some light on the possible creation of such available 
systems scientometric accurate analysis applicable for various severe diseases management. 
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